The U.S. Food and Drug Administration is floating a new idea in its ongoing battle against the opioid crisis—and this time, they’re asking the public to weigh in before making any decisions. Through a formal notice published in the Federal Register, the agency is exploring whether drug companies should be required to provide in-home opioid disposal kits, essentially giving patients a way to destroy unused pills without leaving their house. It’s part of a broader push tied to federal law and ongoing recovery efforts, but what makes this moment interesting isn’t just the proposal—it’s the process behind it.

When agencies like the FDA are considering new rules or guidance, they’re required to go through a public comment process. That’s where the Federal Register comes in. Think of it as the government’s official bulletin board—every proposed rule, request for information, or regulatory change gets published there, and the public is invited to respond. Anyone can submit a comment: individuals, doctors, companies, advocacy groups. And importantly, agencies are legally required to review and consider those comments before moving forward. They don’t just collect them—they analyze them, respond to major arguments, and often adjust policy based on what they receive. In other words, it’s one of the few direct ways everyday people can influence federal decision-making.

In this case, the FDA is asking whether expanding disposal options—like at-home kits—could reduce the risk of unused opioids sitting around and potentially being misused. The concern is real: leftover prescriptions are a major source of diversion, especially within households. But one comment submitted to the docket takes a very different angle, arguing that the focus on disposal may be missing a simpler, more effective solution.

Instead of creating new ways to get rid of unused opioids, the commenter suggests preventing leftovers in the first place by encouraging patients to safely complete their prescribed course under medical guidance. It’s a perspective grounded in data, risk analysis, and a critique of current disposal methods—and because of how the Federal Register process works, this argument will be formally reviewed by the FDA alongside all others.

Here is the full comment as submitted:

I support FDA efforts under the SUPPORT Act and Great American Recovery initiative to curb opioid misuse. However, mandating in-home disposal kits or expanding mail-back/flushing options misses a simpler, evidence-based solution: urge patients to safely finish their prescribed opioid course at home.

Unused pills from legitimate prescriptions drive most diversion and misuse. A 2016 Drug and Alcohol Dependence study found 54% of post-surgery opioids unused after three weeks. SAMHSA surveys show >55% of nonmedical users obtain opioids free from friends/relatives—typically leftovers. Finishing the course eliminates this supply, reducing access for opioid-naïve family members and preventing pediatric exposure or gateway misuse.

Prescribed patients have developed tolerance, making completion far safer for them than for others. Pharmacokinetic data show chronic users require ~4.3x higher fentanyl concentrations for 50% ventilatory depression vs. naïve individuals. Naïve users face exponentially higher overdose risk from diverted doses.

Current disposal methods add unnecessary risks:

A 2017 Science of the Total Environment study deemed flushing listed opioids “negligible” eco-toxicological risk, yet broader concerns persist about pharmaceuticals in waterways. Mail-back envelopes expose postal workers to potential opioid contamination; OIG reports highlight inadequate training for synthetics and rising mail theft.

Home completion avoids flushing pollution, mail hazards, and diversion entirely—no unused pills means no external risks. In-home kits increase cost/complexity with low uptake.

I recommend the FDA:

Prioritize public messaging to “safely finish your prescribed course at home” with physician follow-up. Study this approach before mandating new kits. Include tolerance education in patient info.

This upstream strategy reduces societal harm more effectively.

Thank you for considering this evidence-based alternative.

What stands out here is how the conversation shifts from “what do we do with leftover opioids?” to “why are there leftovers at all?” It’s a subtle but important reframing. The FDA’s proposal focuses on harm reduction after the fact—making disposal easier and safer. The comment, on the other hand, pushes for an upstream solution: eliminate excess supply before it ever becomes a risk.

Whether or not the FDA ultimately adopts any part of this idea, it’s exactly the kind of input the Federal Register system is designed to surface. Competing perspectives, backed by data, laid out in public for policymakers to consider. And with the comment deadline approaching, this debate is still very much open—meaning the final direction could still shift depending on what voices are heard.

IF YOU NEED A LAWYER CONTACT US